RAPP Stock: Price, Earnings History and SEC Filings
Rapport Therapeutics, Inc. (RAPP) last traded at $25.05, up 3.47% on the latest session and down 25.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.19 against an analyst estimate of $-0.93, a miss of 28.0%.
$25.05 +3.47%
1 month-25.45%
52-week high$52.93
52-week low$22.06
Volume926,560
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RAPP earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-1.19 | $-0.93 | -27.96% |
| Mar 2026 | May 7, 2026 | $-0.42 | $-0.56 | +25.00% |
| Dec 2025 | Mar 10, 2026 | $-0.72 | $-0.65 | -10.77% |
| Sep 2025 | Nov 6, 2025 | $-0.71 | $-0.77 | +7.79% |
RAPP beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RAPP
SEC filing data is not available right now. You can search for RAPP on SEC EDGAR.
RAPP news
- Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares FallOct 28, 2026 · finance.yahoo.com
- Rapport Therapeutics stock tumbles on $350M capital raiseOct 28, 2026 · finance.yahoo.com
- Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note RaiseOct 28, 2026 · tikr.com
- Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private PlacementOct 28, 2026 · finance.yahoo.com
- Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private PlacementOct 27, 2026 · finance.yahoo.com
- Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania TrialOct 25, 2026 · marketbeat.com
- Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania DataOct 23, 2026 · finance.yahoo.com
- Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania DataOct 23, 2026 · finance.yahoo.com
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) is a US-listed public company on Nasdaq.